KMT2A and acute myeloid leukemia: Importantly, transcriptional or pharmacological inhibition of KDM4C by molecular or small-molecule inhibitor approaches could significantly lower leukemic burdens and extend the disease latency, particularly in an MLL primary human AML cell xenograft in vivo model.